Ovid Therapeutics Inc. (OVID)
NASDAQ · Healthcare
Ovid Therapeutics Inc. EBITDA 2020–2025
Ovid Therapeutics Inc. annual/quarterly ebitda history and growth rate from 2020 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Ovid Therapeutics Inc. ebitda for the quarter ending March 31, 2026 was -17.8 M, a 43.53% increase year-over-year.
- Ovid Therapeutics Inc. ebitda for the twelve months ending March 31, 2026 was -62.2 M.
- Ovid Therapeutics Inc. annual ebitda for 2025 was -42.2 M, a 31.18% decrease from 2024.
- Ovid Therapeutics Inc. annual ebitda for 2024 was -61.3 M, a 4.36% increase from 2023.
- Ovid Therapeutics Inc. annual ebitda for 2023 was -58.7 M, a 6.68% increase from 2022.
- Ovid Therapeutics Inc. annual ebitda for 2022 was -55.0 M.
EBITDA
TRAILING 12 MONTHS · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Ovid Therapeutics Inc. EBITDA — FAQ
Ovid Therapeutics Inc. (OVID) ebitda over the last 6 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see OVID's ebitda history?
The chart and table above show Ovid Therapeutics Inc.'s ebitda by year and by quarter, including the growth rate.